- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03278743
Tea Consumption and Cognitive Performance in the Very Old
Higher Tea Consumption is Associated With Better Performance on Measures of Attention and Psychomotor Speed in the Very Old: The Newcastle 85+ Study
Studies have found a beneficial effect of tea consumption on the reduction of risk of cognitive impairment and dementia in older aged populations. However, there is a paucity of data on these associations in the very old defined as individuals aged 85 years and over. Therefore, we hypothesized that higher tea consumption was associated with better global and domain-specific cognitive function. We investigated the relationship between tea consumption in the very old and measures of global cognitive function, memory, attention and psychomotor speed.
The Newcastle 85+ Study was a longitudinal (5-years), population-based cohort study of individuals aged 85+ years in North East England, United Kingdom. The final sample included 676 community-dwelling and institutionalized men and women recruited through general medical practices.
Baseline tea consumption was assessed through a 2x24-hr multiple pass recall and longitudinal measures of global and domain specific (memory, speed and attention) cognitive function through the standardized mini-mental state examination and the cognitive drug research system. Linear mixed models, controlling for demographic (e.g. age, sex and education) and health variables were used to determine whether tea consumption was protective against cognitive decline.
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Newcastle upon Tyne, Yhdistynyt kuningaskunta, NE17RU
- Newcastle University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Born in 1921
- Permanently registered with a participating general practice in Newcastle upon Tyne or North Tyneside primary care trusts in the UK
Exclusion Criteria:
- End-stage illness
- Individuals who might pose a safety risk to a nurse visiting alone, with dementia
- Clinical diagnosis of dementia at baseline
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
low to moderate tea consumption
consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
|
Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
|
|
High tea consumption
consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
|
Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Standardized mini-mental state examination
Aikaikkuna: Baseline
|
Measure of global cognition (Score 0-30)
|
Baseline
|
|
Rate of decline of the standardized mini-mental state examination
Aikaikkuna: Baseline to 5 years follow-up
|
Measure of global cognition (Score 0-30)
|
Baseline to 5 years follow-up
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Simple reaction time
Aikaikkuna: Baseline
|
Simple reaction time assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.
The participant is instructed to press "YES" as quickly as possible every time the word "YES" is presented on the screen.
In total, 30 "YES" stimuli are presented with varying inter-stimulus interval.
(ms)
|
Baseline
|
|
Rate of reaction speed decline
Aikaikkuna: Baseline to 3 years follow-up
|
Simple reaction time assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.The participant is instructed to press "YES" as quickly as possible every time the word "YES" is presented on the screen.
In total, 30 "YES" stimuli are presented with varying inter-stimulus interval.
(ms)
|
Baseline to 3 years follow-up
|
|
Choice reaction time
Aikaikkuna: Baseline
|
Choice reaction time assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.
Either the word "YES" or "NO" is presented on the screen and the participant is instructed to press the corresponding button as quickly as possible.
There are 30 trials for each stimulus word, which is chosen randomly with equal probability, with varying inter-stimulus interval.
(ms)
|
Baseline
|
|
Rate of reaction choice decline
Aikaikkuna: Baseline to 3 years follow-up
|
Choice reaction time assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.Either the word "YES" or "NO" is presented on the screen and the participant is instructed to press the corresponding button as quickly as possible.
There are 30 trials for each stimulus word, which is chosen randomly with equal probability, with varying inter-stimulus interval.
(ms)
|
Baseline to 3 years follow-up
|
|
Digit vigilance task
Aikaikkuna: Baseline
|
Digit vigilance task assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.
Target digit is randomly selected and constantly displayed to the right of the screen.
A series of digits (0-9) are presented in the centre of the screen at the rate of 150 per minute.
The participant is required to press the "YES" button as quickly as possible every time the digit in the series matches the target digit.
There are 300 digits in the series and the task lasts for 2 minutes.
(ms)
|
Baseline
|
|
Rate of digit vigilance task decline
Aikaikkuna: Baseline to 3 years follow-up
|
Digit vigilance task assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.
Target digit is randomly selected and constantly displayed to the right of the screen.
A series of digits (0-9) are presented in the centre of the screen at the rate of 150 per minute.
The participant is required to press the "YES" button as quickly as possible every time the digit in the series matches the target digit.
There are 300 digits in the series and the task lasts for 2 minutes.
(ms)
|
Baseline to 3 years follow-up
|
|
Word recognition
Aikaikkuna: Baseline
|
Word recognition was assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.
A list of words is presented on screen for the subject to remember.
Immediately after the presentation the subject is asked to recall as many words as possible.
20 minutes later, the same list of words is presented with added distracter words.
For each word, the subject is asked to indicate whether or not it belongs o the original list by pressing 'YES' or 'NO'.
|
Baseline
|
|
Rate of word recognition decline
Aikaikkuna: Baseline to 3 years follow-up
|
Word recognition was assessed using the Cognitive Drug Research (CDR) computerised system.
The CDR tasks were presented on a hi-resolution Windows-based laptop computer (Motion Computing LE1600 Tablet PC with keyboard accessory) and participants responded using a two-button (NO/YES) response box.A list of words is presented on screen for the subject to remember.
Immediately after the presentation the subject is asked to recall as many words as possible.
20 minutes later, the same list of words is presented with added distracter words.
For each word, the subject is asked to indicate whether or not it belongs to the original list by pressing 'YES' or 'NO'.
|
Baseline to 3 years follow-up
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Tom Kirkwood, Newcastle University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- UNewcastle
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-jaon käyttöoikeuskriteerit
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .